Avadel Pharmaceuticals (NASDAQ:AVDL) (NASDAQ: AVDL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases and central nervous system (CNS) disorders. The company’s lead program, FT218, is an investigational, once-nightly oral formulation of sodium oxybate designed to treat idiopathic hypersomnia. Avadel is also investigating additional pipeline candidates targeting pediatric and adult rare disease indications where current treatment options are limited.
Avadel’s research and development strategy emphasizes formulation innovation to improve patient adherence and quality of life. FT218 has received orphan drug designation from the U.S. Food and Drug Administration for idiopathic hypersomnia, underscoring the company’s commitment to addressing unmet medical needs. In addition to its CNS portfolio, Avadel is exploring preclinical programs for enzyme replacement therapies and other rare disease modalities.
The company maintains its corporate headquarters in Dublin, Ireland, with U.S. operational and clinical support based in St. Petersburg, Florida. Avadel leverages these dual hubs to conduct global clinical trials, engage with regulatory authorities, and manage supply chain activities. Its interdisciplinary teams collaborate with academic institutions and patient advocacy groups to advance the development of novel therapeutic candidates.
Leadership at Avadel is led by President and Chief Executive Officer Vikram Purohit, who brings over two decades of experience in pharmaceutical development and commercialization. Supported by a board of directors and executive team with expertise in clinical research, regulatory affairs, and manufacturing, Avadel continues to advance its pipeline toward potential regulatory approvals and commercialization.
